FILLMED
FILLMED, formerly known as Filorga Medical, was established in 1978 by Dr. Michel Tordjman, a French aesthetic doctor with a focus on cellular biology. The company specializes in developing high-performance anti-aging products for medical aesthetic professionals, including dermatologists, plastic surgeons, and aesthetic practitioners. FILLMED's product range includes dermal fillers, mesotherapy solutions, chemical peels, and advanced skincare products designed to correct signs of aging and improve skin quality. FILLMED's signature products include ART Filler, a range of hyaluronic acid gels with lidocaine for natural results in facial volumization and wrinkle correction, and NCTF® (New Cellular Treatment Factor), a unique injectable solution containing 59 active ingredients and hyaluronic acid, designed to rejuvenate and revitalize the skin. The company is known for its combination protocol treatments, which involve the strategic use of multiple products to maximize their benefits, offering comprehensive and personalized skincare solutions. With a presence in over 75 countries, FILLMED continues to innovate and expand its global reach, supported by HLD Group's investment since 2010. The company's commitment to quality and innovation has made it a leader in the mesotherapy segment, providing minimally invasive treatments that nourish and stimulate the skin to improve its overall health and appearance.